October 2021 Stroke Highlights

HomeStrokeVol. 52, No. 10October 2021 Stroke Highlights Free AccessIn BriefPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree BriefPDF/EPUBOctober Nicole B. Sur, MD SurNicole Sur https://orcid.org/0000-0002-3541-3599 Search for more papers by this author Originally published27 Sep 2021https://doi.org/10.1161/STROKEAHA.121.037103Stroke. 2021;52:3081is related toLong-Term Incidence of and Dementia in ASCOTStroke Prevention Anticoagulants Daily Practice Depending on Atrial Fibrillation Pattern Clinical Risk FactorsEndovascular Therapy Anterior Circulation Tandem OcclusionsStroke FactorsThe effectiveness various anticoagulants stroke prevention atrial fibrillation (AF) the real-world clinical practice setting, as opposed stringent trial has been evaluated previous studies with results. In nested case-referent study, investigators compared direct oral (DOACs) versus vitamin-K antagonists (VKAs) based patient characteristics patterns AF obtained from registry data France. Patients DOACs were younger those VKAs. Although VKA users likely have long-duration (>5 years) permanent AF, apixaban much an incident, short-duration nonpermanent AF. DOAC overall had lower odds incident (ischemic or hemorrhagic) across all types (adjusted ratio=0.66 [95% CI, 0.56–0.79]). There was no significant difference incidence between specific different not ≈3-fold higher stroke, 2.5-fold persistent/paroxysmal group, relative users. The hemorrhagic Overall, results study reflected randomized trials terms efficacy DOACs. Moreover, highlighted use setting. See p 3121.Endovascular Occlusions: Pooled Analysis From TITAN ETIS RegistriesTandem occlusions involving cervical internal carotid artery a distal intracranial branch remain difficult scenario navigate. endovascular therapy anterior circulation is standard care, best management approach tandem occlusion less clear. pooled Endovascular Treatment Ischemic international Thrombectomy Lesions registry. A total 603 patients included 2012 2019 primary outcome modified Rankin Scale score 0–2 (favorable outcome) at 90 days. Acute stenting performed 56.5% cohort. Age admission National Institutes Health similar both groups; however, group rates atherosclerosis general anesthesia use. After adjustment, successful reperfusion favorable days group. also any intracerebral hemorrhage stent after adjustment; there rate symptomatic parenchymal type 2. subgroup analysis, greater benefit stenting, while dissection favored stenting. did evaluate optimal order treatment, authors concluded that acute addition thrombectomy may be safe effective atherosclerotic lesions. More definitive evidence forthcoming ongoing controlled trial. 3097.LONG-TERM INCIDENCE OF STROKE AND DEMENTIA IN ASCOTIn sought determine association preventive interventions ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) long-term dementia 21-year follow-up United Kingdom. lipid-lowering arm comparing statin placebo 3.3 years blood pressure-lowering atenolol-based amlodipine-based regimen 5.5 years. 8850 participants study. Fatal nonfatal occurred 11% cohort, 10.7%. Nonfatal during associated 2-fold developing dementia. allocated atorvastatin numerically events than statistically significant. 21 groups. pressure reduction, fatal strokes Higher variability, but mean pressure, Despite having BP reduction showed positive effect incidence; neither nor amlodipine resulted later follow-up. 3088. Previous Back top Next FiguresReferencesRelatedDetailsRelated articlesLong-Term ASCOTWilliam N. Whiteley, et al. Stroke. 2021;52:3088-3096Stroke FactorsLamiae Grimaldi-Bensouda, 2021;52:3121-3131Endovascular OcclusionsMohammad Anadani, 2021;52:3097-3105 October 2021Vol Issue 10Article InformationMetrics © American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.121.037103 publishedSeptember 27, PDF download Advertisement